Futura Medical Future Growth

Future criteria checks 5/6

Futura Medical is forecast to grow earnings and revenue by 188.3% and 34% per annum respectively while EPS is expected to grow by 188.3% per annum.

Key information

188.3%

Earnings growth rate

188.3%

EPS growth rate

Pharmaceuticals earnings growth19.7%
Revenue growth rate34.0%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Nov 2024

Recent future growth updates

Recent updates

Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)

Sep 13
Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)

We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth

Apr 17
We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation

Jan 05
Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation

Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?

Jul 28
Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?

We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully

Mar 18
We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate

Sep 25
We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate

Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation

May 10
Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation

We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow

Jan 10
We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow

What We Learned About Futura Medical's (LON:FUM) CEO Compensation

Dec 21
What We Learned About Futura Medical's (LON:FUM) CEO Compensation

Earnings and Revenue Growth Forecasts

AIM:FUM - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202620N/A8N/A1
12/31/2025197433
12/31/2024131-3-13
6/30/20248-4-4-2N/A
3/31/20246-5-3-1N/A
12/31/20233-7-11N/A
9/30/20232-6-2-1N/A
6/30/20232-5-3-3N/A
3/31/20231-5-5-4N/A
12/31/2022N/A-6-7-6N/A
9/30/2022N/A-6-6-6N/A
6/30/2022N/A-6-6-5N/A
3/31/2022N/A-5-5-5N/A
12/31/2021N/A-5-4-4N/A
9/30/2021N/A-4-4-4N/A
6/30/2021N/A-3-3-3N/A
3/31/2021N/A-3-4-4N/A
12/31/2020N/A-2-5-5N/A
9/30/20200-4-5-5N/A
6/30/20200-6-6-6N/A
3/31/20200-7-6-6N/A
12/31/20190-9-7-7N/A
9/30/20190-9-6-6N/A
6/30/2019N/A-8-6-6N/A
3/31/2019N/A-7-5-5N/A
12/31/2018N/A-6-5-5N/A
9/30/20180-5-4-4N/A
6/30/20180-4-4-4N/A
3/31/20180-4N/A-4N/A
12/31/20170-4N/A-4N/A
9/30/20170-4N/A-4N/A
6/30/20170-3N/A-4N/A
3/31/20170-4N/A-4N/A
12/31/20160-4N/A-3N/A
9/30/20160-4N/A-4N/A
6/30/20160-5N/A-4N/A
3/31/20160-5N/A-5N/A
12/31/20150-5N/A-5N/A
9/30/20150-5N/A-5N/A
6/30/20150-4N/A-4N/A
3/31/20150-4N/A-4N/A
12/31/20140-3N/A-3N/A
9/30/20140-3N/A-3N/A
6/30/20140-3N/A-3N/A
3/31/20140-2N/A-2N/A
12/31/20130-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FUM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: FUM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FUM is expected to become profitable in the next 3 years.

Revenue vs Market: FUM's revenue (34% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: FUM's revenue (34% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FUM's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Futura Medical plc is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Navid MalikCavendish Historical (Cenkos Securities)
Francesco GregoriEdison Investment Research
Seb JantetPanmure Liberum